logo-loader
viewhVIVO PLC

hVIVO says joint-venture developed malaria drug kicks has moved to the clinic

AGS-v PLUS was developed by Imutex, hVIVO’s joint with a London-based company called the SEEK Group

mosquito
AGS-v PLUS is designed to provoke an immune reaction to the proteins in mosquito saliva

hVIVO PLC (LON:HVO) said a potentially breakthrough vaccine for mosquito-borne diseases is set to undergo a phase I clinical trial.

AGS-v PLUS was developed by Imutex, hVIVO’s joint with a London-based company called the SEEK Group.

The study will be carried out by America’s National Institutes of Health (NIH) at the University of Maryland’s school of medicine.

A multi-national collaboration, additional funding was provided by a UK government body called Innovate UK.

AGS-v PLUS is designed to provoke an immune reaction to the proteins in mosquito saliva, which can carry many diseases such Zika and Malaria.

The vaccine may also have a mosquito-control component, so the trial will also collect data on the fertility of mosquitoes which feed on inoculated volunteers.

"It is great to see the relationship with NIH and the University of Maryland School of Medicine continues as AGS-v PLUS, one of the assets in our joint venture Imutex, moves into the clinic,” said hVIVO chairman Trevor Phillips.

“We are pleased that the development of this asset is continuing with NIAID-funded researchers testing the vaccine and additional funding for the study by Innovate UK."

  • In a separate announcement, the company said finance director Shelley Fraser is leaving to be replaced on an interim basis by Anesh Patel, formerly the company’s head of corporate finance.

Quick facts: hVIVO PLC

Price: - -

LSE:HVO
Market: LSE
Market Cap: -
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of hVIVO PLC named herein, including the promotion by the Company of hVIVO PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

hVIVO merger with Open Orphan 'gives it the chance to achieve profitability'

hVIVO PLC's (LON:HVO) Dr Trevor Phillips caught up with Proactive London's Andrew Scott following the news they're to merge with Open Orphan PLC (LON:ORPH). Open Orphan intends to maintain the existing research and development activities of hVIVO, relative to supporting hVIVO's clinical...

on 10/12/19

2 min read